相关实验视频
Updated: Jun 30, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
巴里西丁尼布用于耐火塔卡亚苏动脉炎:在第三级转诊中心进行前性队列研究
Ziyue Zhou1, Chenglong Fang1, Li Wang2
1Department of Rheumatology and Clinical Immunology, National Clinical Research Center for Dermatologic and Immunologic Diseases, the Ministry of Education Key Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Dongcheng-qu, Beijing, China.
巴里西替尼有效治疗耐火塔卡亚苏动脉炎 (TAK),60%的患者在六个月内反应良好. 这种JAK抑制剂耐受性良好,允许在大多数TAK患者中降低葡萄糖皮质类药物剂量.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 内部医学 内部医学
背景情况:
- 塔卡亚苏动脉炎 (TAK) 是一种罕见的,慢性炎症性疾病,影响大动脉.
- 耐火性TAK病例带来了重大治疗挑战,通常需要先进的治疗方法.
研究的目的:
- 评估巴里西提尼布在耐火性高雅苏动脉炎患者的疗效和安全性.
- 评估在巴里西提尼布治疗期间降低葡萄糖皮质体 (GC) 剂量的可能性.
主要方法:
- 一项前性队列研究,涉及10名耐火TAK患者.
- 患者每天接受巴里西提尼布4毫克与口服葡萄糖皮质类药物联合使用.
主要成果:
- 60%的患者在6个月后实现了整体治疗反应.
- 80%的患者能够逐渐减少或维持他们的GC剂量.
- 一名患者因肝功能障碍而停止服用巴里西提尼布;总体而言,治疗耐受性良好.
结论:
- 巴里西丁尼在治疗耐火的塔卡亚苏动脉炎方面表现出显著的疗效.
- 该药物耐受性良好,并促进TAK患者的葡萄糖皮质体节约.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

